Peptides / Recovery and repair

Natural peptide · 32 amino acids · 3,431.9 Da

Calcitonin-salmon

ApprovedNot banned in sport

Calcitonin-salmon is the salmon form of the hormone calcitonin, approved in the US as a nasal spray for osteoporosis after menopause and in EU countries as an injection. Studies in people tested it mostly on bone, pain and physical function, and tracked side effects. PepBank shows 619 results on calcitonin-salmon from 115 studies in people, and 42 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Miacalcin, Salcatonin, Salmon calcitonin

32 amino acids, from first to last0 changed amino acids

Evidence level: Large trials in people619 of 661 results come from studies in people, including randomized trials.

Results in people

619

94% of 661 results

Results in animals

1% of 661 results

Results in lab cells

5% of 661 results

From computer models

0% of 661 results

Overview

Calcitonin-salmon at a glance

What it is	Natural peptide, 32 amino acids
Approval	Approved in the US and EU (Calcitonin salmon nasal spray)
In sport	Not listed as banned by WADA
Studies	133 studies with results. 131 of them gave calcitonin-salmon, with 661 results. 619 in people9 in animals33 in lab cells
Best study in people	Randomized controlled trial with 4,665 people (2016)
Clinical trials	18 registered: 1 active or planned, 7 with posted results
Community use	Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable

The science

What is calcitonin-salmon?

Calcitonin-salmon has the 32-residue sequence of salmon calcitonin.

Amino acids in one chain

The history of calcitonin-salmon

1969
The oldest paper on calcitonin-salmon in PepBank is from 1969.
2002March
A registered trial of calcitonin-salmon started (NCT00239889).

Calcitonin-salmon structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 32 amino acidsFrom the first amino acid to the last

C1SNLS5TCVLG10+KLSQ−E15LH+KLQ20TYP+RT25NTGSG30TP

Darker means more water-repelling+ and − show charge in the body

Structure

Calcitonin-salmon is a natural peptide of 32 amino acids, with a ring, 1 disulfide bond, no changed amino acids.

Formula

C₁₄₅H₂₄₀N₄₄O₄₈S₂

Molecular weight

3,431.9 g/mol

CAS number

47931-85-1

Target

Calcitonin receptor (gene CALCR): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 16133812, ChEMBL CHEMBL3989767, UNII 7SFC6U2VI5, DrugBank DB00017

Full sequence, SMILES and InChIKey

InChIKey
BBBFJLBPOGFECG-VJVYQDLKSA-N

SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)CC(C)C)CC(=O)N)CO)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N)O

See charge, composition and 3D structure on the Scientific page

The evidence

What calcitonin-salmon studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people619 of 661 results come from studies in people, including randomized trials.

Bones and joints

361 results · 346 in people · 4 animal · 11 lab

In women with postmenopausal osteoporosis, SMC021 did not prevent new vertebral fractures compared with placebo. Bone, 2016

Top results

In women with postmenopausal osteoporosis, SMC021 did not prevent new vertebral fractures compared with placebo. (Bone, 2016)
In premenopausal and early postmenopausal women, serum calcium changed significantly after each of the four sCT administrations. (The Journal of clinical endocrinology and metabolism, 1991)
In CSMC021C2301, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo. (Osteoarthritis and cartilage, 2015)

Pain

52 results · 52 in people

In women with osteoporosis and back pain, salmon calcitonin improved pain more than placebo. Clinical rheumatology, 2007

Top results

In women with osteoporosis and back pain, salmon calcitonin improved pain more than placebo. (Clinical rheumatology, 2007)
In postoperative patients, salmon calcitonin plus lidocaine reduced pain more than lidocaine plus saline. (Anesthesia and analgesia, 1987)
In postmenopausal women with osteoporosis and back pain, pain effects did not differ significantly between salmon calcitonin with calcium and calcium alone. (European spine journal, 2006)

Salt, water and minerals

37 results · 37 in people

In cancer-related hypercalcemia, salmon calcitonin achieved normocalcemia less often than gallium nitrate. Annals of internal medicine, 1988

Top results

In cancer-related hypercalcemia, salmon calcitonin achieved normocalcemia less often than gallium nitrate. (Annals of internal medicine, 1988)
In postmenopausal osteoporosis, blood calcium was significantly lower with salmon calcitonin than control at 4 months. (Metabolism: clinical and experimental, 1984)
In normal subjects, salmon calcitonin reduced intestinal calcium absorption by 58% from basal conditions. (The Journal of clinical endocrinology and metabolism, 1976)

Daily life and fitness

32 results · 32 in people

In postmenopausal women with osteoporosis and back pain, disability effects did not differ significantly between salmon calcitonin with calcium and calcium alone. European spine journal, 2006

Top results

In postmenopausal women with osteoporosis and back pain, disability effects did not differ significantly between salmon calcitonin with calcium and calcium alone. (European spine journal, 2006)
In women with osteoporosis and back pain, salmon calcitonin improved quality of life more than placebo. (Clinical rheumatology, 2007)
In patients with reflex sympathetic dystrophy, salmon calcitonin improved movement range compared with placebo with physiotherapy. (Pain, 1992)

Kidneys and bladder

6 results · 6 in people

In malignant hypercalcemia, added calcitonin was linked to a lower renal calcium reabsorption setting than APD alone. Archives of internal medicine, 1990

Top results

In malignant hypercalcemia, added calcitonin was linked to a lower renal calcium reabsorption setting than APD alone. (Archives of internal medicine, 1990)
In normal subjects, blood sodium did not increase after rectal salmon calcitonin, whereas it increased in untreated controls. (Calcified tissue international, 1987)
In volunteers, nasal and suppository salmon calcitonin showed activity in the kidneys. (Clinical orthopaedics and related research, 1987)

Blood sugar

6 results · 5 in people · 1 lab

In both groups, salmon calcitonin reduced insulin responses to glucose compared with testing without calcitonin. The Journal of clinical endocrinology and metabolism, 1981

Top results

In both groups, salmon calcitonin reduced insulin responses to glucose compared with testing without calcitonin. (The Journal of clinical endocrinology and metabolism, 1981)
In lab tests with rat muscle, salmon calcitonin reduced insulin-stimulated sugar incorporation into glycogen compared with insulin stimulation alone. (Molecular pharmacology, 1993)
In both groups, salmon calcitonin reduced C-peptide responses to glucose compared with testing without calcitonin. (The Journal of clinical endocrinology and metabolism, 1981)

Calcitonin-salmon has 1,643 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 133 calcitonin-salmon studies by area Open the Scientific page

Key calcitonin-salmon studies

Studies in people come first, then studies in animals and in the lab.

People
A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D
Henriksen et al. 2016 · Bone · 4,665 people · cited by 54
17 results
People
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
Karsdal et al. 2015 · Osteoarthritis and cartilage · 1,176 people · cited by 109
3 results
People
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
Chesnut et al. 2000 · The American journal of medicine · 817 people · cited by 585
7 results
People
Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin
Reginster et al. 1994 · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 186 people · cited by 40
3 results
People
A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
Reginster et al. 1994 · European journal of clinical investigation · 87 people · cited by 24
4 results

All 133 Calcitonin-salmon studies

Calcitonin-salmon clinical trials

ClinicalTrials.gov lists 18 trials of calcitonin-salmon. 1 is active or planned, and 7 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Phase 3terminated1,030 planned

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

Phase 3completed565 people

A Study for Patients With Osteoporosis

Phase 3completed364 people

All 10 Calcitonin-salmon trials

Status and safety

Is calcitonin-salmon approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Calcitonin salmon nasal spray). The FDA label for Calcitonin salmon nasal spray says: “Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Calcitonin-salmon side effects and safety

PepBank has 58 safety results from studies of calcitonin-salmon. 58 of them come from studies in people.

Safety results from studies (58)

In women with postmenopausal osteoporosis, approximately 92% of both SMC021 and placebo groups had adverse events, mostly mild or moderate. (Bone, 2016)
In women with postmenopausal osteoporosis, approximately 80% of each oral rsCT, nasal ssCT, and placebo group had adverse events. (Journal of bone and mineral research, 2012)
In postmenopausal women with low bone mass, calcitonin and placebo had comparable overall safety profiles. (Osteoporosis international, 2014)
In women with osteoporosis, adverse event rates were similar with salmon calcitonin and teriparatide. (Current medical research and opinion, 2006)
In acute pancreatitis, salmon calcitonin did not change mortality compared with placebo. (Scandinavian journal of gastroenterology, 1979)
In men with osteoporosis, no premature discontinuations were reported with calcitonin nasal spray, compared with the control group. (Bone, 2005)
Five patients in each treatment group withdrew during the second year. (Thorax, 1994)
In patients with vertebral fractures, nasal and injected calcitonin had comparable general safety. (Calcified tissue international, 1997)
In postmenopausal women, calcitonin was well tolerated without significant treatment-related adverse events. (Calcified tissue international, 1996)
In early postmenopausal women, nasal discomfort occurred in one salmon calcitonin recipient and one placebo recipient. (Calcified tissue international, 1995)
In postmenopausal women with osteoporosis, no serious side effects occurred during salmon calcitonin treatment. (International journal of clinical practice, 2001)
No side effects occurred with salmon calcitonin plus APD or APD alone. (Archives of internal medicine, 1990)
Eleven calcitonin recipients withdrew, including seven for severe side effects, three for noncompliance, and one for asthma exacerbation. (The American review of respiratory disease, 1990)
Patients in the nasal salmon calcitonin study reported no major side effects. (Clinical therapeutics, 1989)
In women with osteoporosis, no subjective side effects occurred during salmon calcitonin treatment. (Clinical endocrinology, 1989)
In psychiatric inpatients, salmon calcitonin appeared to increase depression temporarily in a trial with placebo. (Archives of general psychiatry, 1979)
In Paget disease, no patient stopped salmon calcitonin suppository therapy. (Clinical orthopaedics and related research, 1987)
All patients with multiple myeloma tolerated salmon calcitonin. (Bone and mineral, 1990)
Ten patients with fibromyalgia had nausea during calcitonin treatment. (Scandinavian journal of rheumatology, 1998)
Some healthy volunteers who received oral salmon calcitonin had mild, temporary nausea. (Journal of bone and mineral research, 2002)
In postmenopausal women taking oral calcitonin, mild to moderate digestive symptoms were seen, mainly at high doses. (Journal of bone and mineral research, 2004)
In renal transplant recipients, two calcitonin-treated patients had temporary low blood calcium. (Kidney international, 2005)
Men who received salmon calcitonin had no reported treatment-related adverse events. (Journal of bone and mineral research, 2002)
Patients with recent osteoporosis-related spine fractures had dizziness during salmon calcitonin suppository treatment. (The Clinical journal of pain, 1999)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.8 mg/day	Human	human	oral	36 months	Randomized trial in people · n = 4,665	Henriksen 2016
0.8 mg twice daily	Human	human	oral	24 months	Randomized trial in people · n = 1,176	Karsdal 2015
200 IU daily	Human	human	intranasal	5 years	Randomized trial in people · n = 557	Chesnut 2000
50 IU/day, 5 days per week	Human	human	intranasal	3 years	Randomized trial in people · n = 186	Reginster 1994
50 IU daily, 5 days per week	Human	human	intranasal	5 years	Randomized trial in people · n = 87	Reginster 1994
100 IU	Human	human	intranasal	1 year	Randomized trial in people	Overgaard 1989
100 IU	Human	human	subcutaneous	2 weeks	Randomized trial in people · n = 56	Ofluoglu 2007
0.8 mg	Human	human	oral	Not reported	Randomized trial in people	Karsdal 2008
0.15, 0.4, 1.0, or 2.5 mg daily; or 1.0 mg every other day	Human	human	oral	3 months	Randomized trial in people · n = 277	Tankó 2004
0.15, 0.4, 1.0, or 2.5 mg	Human	human	oral	3 months	Randomized trial in people · n = 152	Bagger 2005
100 IU daily	Human	human	intranasal	Not reported	Randomized trial in people · n = 120	Arnala 1996
200 IU daily or three times weekly	Human	human	intranasal	2 years	Randomized trial in people · n = 117	Ellerington 1996
200 IU daily	Human	human	intranasal	three months	Randomized trial in people · n = 110	Papadokostakis 2006
100 IU/day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 104	Kung 2006
3 x 20 micrograms = 300 MRCU daily	Human	human	intravenous	6 days	Randomized trial in people · n = 94	Goebell 1979
100, 200, or 400 IU	Human	human	intranasal	2 years	Randomized trial in people · n = 91	Overgaard 1994
200 IU daily, 1 month on-1 month off	Human	human	intranasal	1 year	Randomized trial in people · n = 91	Kaskani 2005
200 IU/d	Human	human	intranasal	2 years	Randomized trial in people · n = 81	Overgaard 1995
50 IU/day for 5 days per week	Human	human	intranasal	12 months	Randomized trial in people · n = 79	Reginster 1987
200 IU daily during alternate months	Human	human	intranasal	18 months	Randomized trial in people · n = 71	Tóth 2005
3 x 100 U/day	Human	human	intranasal	Not reported	Randomized trial in people · n = 66	Gobelet 1992
100 IU daily	Human	human	subcutaneous	6 months	Randomized trial in people · n = 63	Hwang 2006
100 IU/day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 63	Hay 2001
200 IU daily	Human	human	intranasal	24 months	Randomized trial in people · n = 62	Thamsborg 1996
100 IU	Human	human	subarachnoid	Not reported	Randomized trial in people · n = 60	Miralles 1987
8 IU/kg every 6 hours	Human	human	intramuscular	5 days	Randomized trial in people · n = 50	Warrell 1988
200 IU daily	Human	human	intranasal	three months	Randomized trial in people · n = 50	Karachalios 2004
200 U/day	Human	human	Not reported	8 weeks	Randomized trial in people · n = 45	Sahin 2009
200 IU every other day	Human	human	intranasal	2 years	Randomized trial in people · n = 44	Luengo 1994
0.8 mg	Human	human	oral	Not reported	Randomized trial in people · n = 42	Karsdal 2008
100 IU three times weekly	Human	human	subcutaneous	2 years	Randomized trial in people · n = 40	Healey 1996
200 IU daily	Human	human	rectal suppository	28 days	Randomized trial in people · n = 40	Lyritis 1999
100 IU daily	Human	human	subcutaneous	28 days	Randomized trial in people · n = 40	Roth 1986
200 IU/day	Human	human	Not reported	2 months	Randomized trial in people · n = 35	Sahin 2006
200 IU daily	Human	human	intranasal	12 months	Randomized trial in people · n = 28	Trovas 2002
200 UI 6-hourly	Human	human	subcutaneous	48 h	Randomized trial in people · n = 25	Hindley 1982
200 IU every other day	Human	human	intranasal	6 months	Randomized trial in people · n = 21	Gennari 1992
100 Medical Research Council Units	Human	human	Not reported	Not reported	Randomized trial in people · n = 16	Passariello 1981
200 IU/day	Human	human	intranasal	Not reported	Randomized trial in people · n = 14	de 2006
100 IU daily	Human	human	intranasal	5 years	Randomized trial in people	Chesnut 2000

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The selected US label describes prescription nasal treatment for a restricted postmenopausal patient group. This record gives label information.

Reported routines and cautions

What people use it for

Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitableS1

Reported regimens

Regimens that community sources report for Calcitonin-salmon. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitableOfficial label dosing of an approved product	intranasalOne spray into one nostril, with nostrils alternated daily.	200 IU per dose	once daily	Not stated	Single official US label source.	S1

Cautions

The US label reports a possible malignancy association and requires periodic reassessment of continued treatment. Hypersensitivity, hypocalcemia, and nasal injury require attention.S1
The EMA review found evidence of a small increased cancer risk with long-term calcitonin use. It concluded that the benefits did not outweigh risks for osteoporosis.S2

Status notes

The EMA referral ended nasal calcitonin use for osteoporosis. Nationally authorised injection or infusion products retain restricted indications. The shortest possible treatment and smallest effective dose apply.S2

Community sources

S1Calcitonin salmon nasal spray US prescribing information (Apotex) (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

No separately verified non-vendor community regimen is included. This record covers one selected US nasal label regimen. It does not reproduce the full label or establish a fixed treatment duration.

Questions and more

Ask a question about calcitonin-salmon

The answer links to every study it uses.

What does the evidence say about calcitonin-salmon?Is calcitonin-salmon tested in people?Compare with Teriparatide (PTH 1-34)Compare with Thymosin beta-4 (human)

Sources

Database: PepBank data for calcitonin-salmon (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about calcitonin-salmon

Calcitonin-salmon

ApprovedNot banned in sport

Also known as Miacalcin, Salcatonin, Salmon calcitonin

What it is

Natural peptide, 32 amino acids

Approval

Approved in the US and EU (Calcitonin salmon nasal spray)

In sport

Not listed as banned by WADA

Studies

133 studies with results. 131 of them gave calcitonin-salmon, with 661 results.
619 in people9 in animals33 in lab cells

Best study in people

Randomized controlled trial with 4,665 people (2016)

Clinical trials

18 registered: 1 active or planned, 7 with posted results

Community use

Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable

Dose as reported

Class

Species

Route

Duration

Design

Source

0.8 mg/day

Human

human

oral

36 months

Randomized trial in people · n = 4,665

Henriksen 2016

0.8 mg twice daily

Human

human

oral

24 months

Randomized trial in people · n = 1,176

Karsdal 2015

200 IU daily

Human

human

intranasal

5 years

Randomized trial in people · n = 557

Chesnut 2000

50 IU/day, 5 days per week

Human

human

intranasal

3 years

Randomized trial in people · n = 186

Reginster 1994

50 IU daily, 5 days per week

Human

human

intranasal

5 years

Randomized trial in people · n = 87

Reginster 1994

100 IU

Human

human

intranasal

1 year

Randomized trial in people

Overgaard 1989

100 IU

Human

human

subcutaneous

2 weeks

Randomized trial in people · n = 56

Ofluoglu 2007

0.8 mg

Human

human

oral

Not reported

Randomized trial in people

Karsdal 2008

0.15, 0.4, 1.0, or 2.5 mg daily; or 1.0 mg every other day

Human

human

oral

3 months

Randomized trial in people · n = 277

Tankó 2004

0.15, 0.4, 1.0, or 2.5 mg

Human

human

oral

3 months

Randomized trial in people · n = 152

Bagger 2005

100 IU daily

Human

human

intranasal

Not reported

Randomized trial in people · n = 120

Arnala 1996

200 IU daily or three times weekly

Human

human

intranasal

2 years

Randomized trial in people · n = 117

Ellerington 1996

200 IU daily

Human

human

intranasal

three months

Randomized trial in people · n = 110

Papadokostakis 2006

100 IU/day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 104

Kung 2006

3 x 20 micrograms = 300 MRCU daily

Human

human

intravenous

6 days

Randomized trial in people · n = 94

Goebell 1979

100, 200, or 400 IU

Human

human

intranasal

2 years

Randomized trial in people · n = 91

Overgaard 1994

200 IU daily, 1 month on-1 month off

Human

human

intranasal

1 year

Randomized trial in people · n = 91

Kaskani 2005

200 IU/d

Human

human

intranasal

2 years

Randomized trial in people · n = 81

Overgaard 1995

50 IU/day for 5 days per week

Human

human

intranasal

12 months

Randomized trial in people · n = 79

Reginster 1987

200 IU daily during alternate months

Human

human

intranasal

18 months

Randomized trial in people · n = 71

Tóth 2005

3 x 100 U/day

Human

human

intranasal

Not reported

Randomized trial in people · n = 66

Gobelet 1992

100 IU daily

Human

human

subcutaneous

6 months

Randomized trial in people · n = 63

Hwang 2006

100 IU/day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 63

Hay 2001

200 IU daily

Human

human

intranasal

24 months

Randomized trial in people · n = 62

Thamsborg 1996

100 IU

Human

human

subarachnoid

Not reported

Randomized trial in people · n = 60

Miralles 1987

8 IU/kg every 6 hours

Human

human

intramuscular

5 days

Randomized trial in people · n = 50

Warrell 1988

200 IU daily

Human

human

intranasal

three months

Randomized trial in people · n = 50

Karachalios 2004

200 U/day

Human

human

Not reported

8 weeks

Randomized trial in people · n = 45

Sahin 2009

200 IU every other day

Human

human

intranasal

2 years

Randomized trial in people · n = 44

Luengo 1994

0.8 mg

Human

human

oral

Not reported

Randomized trial in people · n = 42

Karsdal 2008

100 IU three times weekly

Human

human

subcutaneous

2 years

Randomized trial in people · n = 40

Healey 1996

200 IU daily

Human

human

rectal suppository

28 days

Randomized trial in people · n = 40

Lyritis 1999

100 IU daily

Human

human

subcutaneous

28 days

Randomized trial in people · n = 40

Roth 1986

200 IU/day

Human

human

Not reported

2 months

Randomized trial in people · n = 35

Sahin 2006

200 IU daily

Human

human

intranasal

12 months

Randomized trial in people · n = 28

Trovas 2002

200 UI 6-hourly

Human

human

subcutaneous

48 h

Randomized trial in people · n = 25

Hindley 1982

200 IU every other day

Human

human

intranasal

6 months

Randomized trial in people · n = 21

Gennari 1992

100 Medical Research Council Units

Human

human

Not reported

Randomized trial in people · n = 16

Passariello 1981

200 IU/day

Human

human

intranasal

Not reported

Randomized trial in people · n = 14

de 2006

100 IU daily

Human

human

intranasal

5 years

Randomized trial in people

Chesnut 2000

Context

Route

Amount

How often

How long

Agreement

Sources

Postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitableOfficial label dosing of an approved product

intranasalOne spray into one nostril, with nostrils alternated daily.

200 IU per dose

once daily

Not stated

Single official US label source.

Calcitonin-salmon

Calcitonin-salmon at a glance

What is calcitonin-salmon?

The history of calcitonin-salmon

Calcitonin-salmon structure and chemistry

What calcitonin-salmon studies show

Bones and joints

Pain

Salt, water and minerals

Daily life and fitness

Kidneys and bladder

Blood sugar

Key calcitonin-salmon studies

Calcitonin-salmon clinical trials

Is calcitonin-salmon approved?

Calcitonin-salmon side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about calcitonin-salmon

Related peptides

Sources

Calcitonin-salmon

Calcitonin-salmon at a glance

What is calcitonin-salmon?

The history of calcitonin-salmon

Calcitonin-salmon structure and chemistry

What calcitonin-salmon studies show

Bones and joints

Pain

Salt, water and minerals

Daily life and fitness

Kidneys and bladder

Blood sugar

Key calcitonin-salmon studies

Calcitonin-salmon clinical trials

Is calcitonin-salmon approved?

Calcitonin-salmon side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about calcitonin-salmon

Related peptides

Sources